Amarin Corp Plc (AMRN)

[sts66]

the case in question was the FDA vs. a single rep, the drug company/distributor was not involved - not the same as GSK being fined $3B for promoting off label use of Paxil and Wellbutrin. So individual reps could, on their own decision, promote the V + statin usage, but not using any materials directly created and supplied by Kowa or AMRN. I believe they are allowed to provide contact info at the company(s) for the docs to get further information if they desire, and that's ok because it's doctor initiated - docs can pull, but reps can't push.